🔗 Share this article The Global Health Body Issues Alert Over Critical Lack of Obesity Jabs Less than one in 10 people eligible to benefit from GLP-1 drugs like Wegovy can access them, warns the WHO as it issues its first recommendations on the drugs. Given more than one billion individuals worldwide now living with obesity, it is calling for broader and more equitable availability to GLP-1 medication. According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken. "Our latest guidelines affirms that excess weight is a lifelong illness that can be addressed with thorough and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are significant hurdles to broad access to the injections that can aid individuals in losing substantial body mass, says the body. Weight-Loss Drug Shortage Even under the present most optimistic scenario, the production of such drugs would only suffice for about 100 million people – under 10% of eligible patients, as stated by the WHO. The guideline urges countries and companies to increase access, by approaches such as patent sharing. The intellectual property rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is due to expire in several countries in 2026. How Obesity Drugs Function These medications imitate a natural hormone to slow digestion, curb appetite and enhance satiety so people eat less. Individuals commonly start to lose weight within a few weeks of beginning the once-weekly jabs. Research points to patients may regain a significant portion a year later of discontinuing the treatment, as their typical food cravings come back. To be carrying excess weight increases your risk for experiencing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies. Obesity concerns people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.
Less than one in 10 people eligible to benefit from GLP-1 drugs like Wegovy can access them, warns the WHO as it issues its first recommendations on the drugs. Given more than one billion individuals worldwide now living with obesity, it is calling for broader and more equitable availability to GLP-1 medication. According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken. "Our latest guidelines affirms that excess weight is a lifelong illness that can be addressed with thorough and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are significant hurdles to broad access to the injections that can aid individuals in losing substantial body mass, says the body. Weight-Loss Drug Shortage Even under the present most optimistic scenario, the production of such drugs would only suffice for about 100 million people – under 10% of eligible patients, as stated by the WHO. The guideline urges countries and companies to increase access, by approaches such as patent sharing. The intellectual property rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is due to expire in several countries in 2026. How Obesity Drugs Function These medications imitate a natural hormone to slow digestion, curb appetite and enhance satiety so people eat less. Individuals commonly start to lose weight within a few weeks of beginning the once-weekly jabs. Research points to patients may regain a significant portion a year later of discontinuing the treatment, as their typical food cravings come back. To be carrying excess weight increases your risk for experiencing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies. Obesity concerns people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.